Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.50 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.50 |
| ▸ | ATM | Q13315 | 2/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.50 |
| ▸ | MEN1 | O00255 | 1/20 | 0.48 |
| ▸ | FGB | P02675 | 1/20 | 0.48 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.48 |
| ▸ | HSP90AB1 | P08238 | 1/20 | 0.48 |
| ▸ | MAPT | P10636 | 1/20 | 0.48 |
| ▸ | HPGD | P15428 | 1/20 | 0.48 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.48 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.48 |
| ▸ | HTT | P42858 | 1/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.48 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.48 |
| ▸ | BAZ2B | Q9UIF8 | 1/20 | 0.46 |
| ▸ | CASP3 | P42574 | 1/20 | 0.46 |
| ▸ | BRD4 | O60885 | 1/20 | 0.45 |
| ▸ | CA12 | O43570 | 1/20 | 0.45 |
| ▸ | CA1 | P00915 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29446230 | 1.00 | SMN1; SMN2 (0.50) | SMN1; SMN2NPSR1ATMALDH1A1MEN1 | |
| SCHEMBL2258053 | 0.97 | ALDH1A1 (0.50) | SMN1; SMN2NPSR1ATMALDH1A1MEN1 | |
| SCHEMBL484748 | 0.90 | PBRM1 (0.51) | SMN1; SMN2NPSR1ATMALDH1A1MAPT | |
| SCHEMBL353895 | 0.88 | BAZ2B (0.56) | SMN1; SMN2NPSR1ATMALDH1A1MEN1 | |
| SCHEMBL13727452 | 0.84 | BAZ2B (0.52) | SMN1; SMN2NPSR1ATMALDH1A1MEN1 | |
| SCHEMBL9587300 | 0.84 | SRD5A1 (0.46) | SMN1; SMN2NPSR1ATMALDH1A1MEN1 | |
| SCHEMBL18159338 | 0.82 | NPC1 (0.53) | SMN1; SMN2NPSR1ALDH1A1MEN1MAPT | |
| SCHEMBL883530 | 0.82 | ALDH1A1 (0.61) | SMN1; SMN2ATMALDH1A1MEN1MAPT | |
| SCHEMBL9175124 | 0.81 | MAOA (0.40) | SMN1; SMN2NPSR1ATMALDH1A1MEN1 | |
| SCHEMBL17276101 | 0.81 | MAPT (0.44) | SMN1; SMN2NPSR1ATMALDH1A1MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 74 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12350270-B2 | Antimalarial agents | MSD R&D (CHINA) CO. LTD. (CN) | 2025-07-08 | — | — | US | disclosed |
| EP-3145915-B1 | ANTIDIABETIC TRICYCLIC COMPOUNDS | MERCK SHARP & DOHME LLC (US) | 2025-03-19 | — | — | EP | disclosed |
| US-20230355622-A1 | METHODS OF CHEMOVACCINATION AGAINST PLASMODIUM INFECTIONS | MERCK SHARP & DOHME LLC (US) | 2023-11-09 | — | — | US | disclosed |
| US-20230355622-A1 | METHODS OF CHEMOVACCINATION AGAINST PLASMODIUM INFECTIONS | MERCK SHARP & DOHME LLC (US) | 2023-11-09 | — | — | US | disclosed |
| US-20230355622-A1 | METHODS OF CHEMOVACCINATION AGAINST PLASMODIUM INFECTIONS | MERCK SHARP & DOHME LLC (US) | 2023-11-09 | — | — | US | disclosed |
| EP-4216957-A1 | METHODS OF CHEMOVACCINATION AGAINST PLASMODIUM INFECTIONS | Merck Sharp & Dohme LLC (US) | 2023-08-02 | — | — | EP | disclosed |
| US-20220331321-A1 | ANTIMALARIAL AGENTS | MERCK SHARP & DOHME CORP. (US) | 2022-10-20 | — | — | US | disclosed |
| US-20220331321-A1 | ANTIMALARIAL AGENTS | MERCK SHARP & DOHME CORP. (US) | 2022-10-20 | — | — | US | disclosed |
| CN-114555564-A | Antimalarial drugs | 默沙东公司 | 2022-05-27 | — | — | CN | disclosed |
| WO-2022066545-A1 | METHODS OF CHEMOVACCINATION AGAINST PLASMODIUM INFECTIONS | MERCK SHARP & DOHME CORP. (US) | 2022-03-31 | — | — | WO | disclosed |
| EP-0699209-A1 | PROCESSES AND INTERMEDIATE COMPOUNDS USEFUL FOR THE PREPARATION OF PLATELET GLYCOPROTEIN IIb/IIIa INHIBITORS | THE DU PONT MERCK PHARMACEUTICAL COMPANY (US) | 1996-03-06 | — | — | EP | disclosed |
| EP-0692982-A1 | RADIOLABELED PLATELET GPIIb/IIIa RECEPTOR ANTAGONISTS AS IMAGING AGENTS FOR THE DIAGNOSIS OF THROMBOEMBOLIC DISORDERS | THE DU PONT MERCK PHARMACEUTICAL COMPANY (US) | 1996-01-24 | — | — | EP | disclosed |
| EP-0691987-A1 | CYCLIC COMPOUNDS USEFUL AS INHIBITORS OF PLATELET GLYCOPROTEIN IIb/IIIa | THE DU PONT MERCK PHARMACEUTICAL COMPANY (US) | 1996-01-17 | — | — | EP | disclosed |
| WO-1995023811-A1 | NOVEL CARBOCYCLIC COMPOUNDS WHICH INHIBIT PLATELET AGGREGATION BY INTERACTION WITH THE GPIIB/IIIA RECEPTOR COMPLEX | THE DU PONT MERCK PHARMACEUTICAL COMPANY (US) | 1995-09-08 | — | — | WO | disclosed |
| US-5405844-A | Tetracyclic antibiotics and processes for their preparation | HOECHST AKTIENGESELLSCHAFT (DE) | 1995-04-11 | — | — | US | disclosed |
| WO-1994026779-A1 | PROCESSES AND INTERMEDIATE COMPOUNDS USEFUL FOR THE PREPARATION OF PLATELET GLYCOPROTEIN IIb/IIIa INHIBITORS | THE DU PONT MERCK PHARMACEUTICAL COMPANY (US) | 1994-11-24 | — | — | WO | disclosed |
| EP-0625164-A1 | CYCLIC COMPOUNDS USEFUL AS INHIBITORS OF PLATELET GLYCOPROTEIN IIb/IIIa | THE DU PONT MERCK PHARMACEUTICAL COMPANY (US) | 1994-11-23 | — | — | EP | disclosed |
| WO-1994022910-A1 | CYCLIC COMPOUNDS USEFUL AS INHIBITORS OF PLATELET GLYCOPROTEIN IIb/IIIa | THE DU PONT MERCK PHARMACEUTICAL COMPANY (US) | 1994-10-13 | — | — | WO | disclosed |
| WO-1994022494-A1 | RADIOLABELED PLATELET GPIIb/IIIa RECEPTOR ANTAGONISTS AS IMAGING AGENTS FOR THE DIAGNOSIS OF THROMBOEMBOLIC DISORDERS | THE DU PONT MERCK PHARMACEUTICAL COMPANY (US) | 1994-10-13 | — | — | WO | disclosed |
| WO-1993007170-A1 | CYCLIC COMPOUNDS USEFUL AS INHIBITORS OF PLATELET GLYCOPROTEIN IIb/IIIa | THE DU PONT MERCK PHARMACEUTICAL COMPANY (US) | 1993-04-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12350270-B2 | Antimalarial agents | CTSL, SERPINA3, SERPINB1 | SMN1; SMN2 3474/4885NPSR1 2341/4885ATM 4665/4885 |
| US-20230355622-A1 | METHODS OF CHEMOVACCINATION AGAINST PLASMODIUM INFECTIONS | CTSL, PRCP, CPB1 | SMN1; SMN2 4402/4885NPSR1 3039/4885ATM 4353/4885 |
| US-20220331321-A1 | ANTIMALARIAL AGENTS | CTSL, SERPINA3, SERPINB1 | SMN1; SMN2 3474/4885NPSR1 2341/4885ATM 4665/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.